<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124042</url>
  </required_header>
  <id_info>
    <org_study_id>XT-150-2-0204</org_study_id>
    <nct_id>NCT04124042</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of XT-150 in Osteoarthritis of the Knee</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xalud Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xalud Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing
      moderate to severe pain due to osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing
      moderate to severe pain due to osteoarthritis of the knee.

      Baseline confirmation of study eligibility will be completed the day before or day of study
      drug administration.

      Study drug will be administered by intra-articular (IA) injection into the joint space of the
      knee.

      Up to 270 participants will be randomly enrolled into 1 of 3 treatment groups (90
      participants/ group). Treatment Groups:

        1. Placebo (1 mL)

        2. Low dose XT-150 (1 mL)

        3. High dose XT-150 (1 mL)

      The study will be conducted in 2 stages, A and B:

      A. Placebo-controlled for 6 months

      B. Continued follow up for 6 months with the option of receiving one of two doses of XT-150
      injection to the index knee.

      Final assessments will be 12 months after the first IA dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, blinded, placebo-controlled, study of pain due to OA of the knee</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score(KOOS)/Western Ontario and McMasters Arthritis Index (WOMAC)</measure>
    <time_frame>12 months</time_frame>
    <description>Responder Rates in KOOS/WOMAC scores, higher KOOS scores and lower WOMAC scores indicate improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Interference</measure>
    <time_frame>12 month</time_frame>
    <description>Response rates in all dimensions of the short-form Brief Pain Inventory and Interference, lower scores indicate improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>12 months</time_frame>
    <description>OA question, &quot;Considering all the ways the OA in your knee affects you, how are you doing today?&quot; on scale of 1-5, with 5 as worst</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose XT-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose active, experimental treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose XT-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose active, experimental treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XT-150</intervention_name>
    <description>plasmid DNA</description>
    <arm_group_label>High Dose XT-150</arm_group_label>
    <arm_group_label>Low Dose XT-150</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic disease due to osteoarthritis, defined as a WOMAC Pain score ≥ 8 (worst
             possible = 20)

          2. Focused Analgesia Selection Test will be used to determine whether patients can report
             pain with sufficient consistency to enter the clinical trial

          3. Males and females between 45 and 85 years of age, inclusive

          4. Kellgren-Lawrence grading of 2 or 3 within the last 6 months

          5. Stable analgesic regimen during the 4 weeks prior to enrollment

          6. In the judgment of the Investigator, acceptable general medical condition

          7. Life expectancy &gt;6 months

          8. Male and female participants who are heterosexually active and not surgically sterile
             must agree to use effective contraception, including abstinence, for the duration of
             the study

          9. Have suitable knee joint anatomy for intra-articular injection

         10. Willing and able to return for the follow-up (FU) visits

         11. Able to read and understand study instructions, and willing and able to comply with
             all study procedures

        Exclusion Criteria:

          1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study
             drug, including double-stranded DNA, mannose, and sucrose

          2. Previously received XT-150 injection(s)

          3. Scheduled partial or complete knee replacement within 6 months; participant agrees not
             to schedule a knee replacement during Stage A of the study

          4. History of knee arthroplasty on the Index Knee, i.e., selected for study injection(s)

          5. History of rheumatoid arthritis or other inflammatory disease

          6. History of immunosuppressive therapy; systemic steroids in the last 3 months

          7. Received knee injection with hyaluronic acid or stem-cells in the last 6 months

          8. Knee injection of glucocorticoid in the last 3 months

          9. Current treatment with systemic immunosuppressive (systemic corticosteroid therapy or
             other strong immunosuppressant)

         10. Currently receiving systemic chemotherapy or radiation therapy for malignancy

         11. Clinically significant hepatic disease as indicated by clinical laboratory results ≥3
             times the upper limit of normal for any liver function test (e.g., aspartate
             aminotransferase, alanine aminotransferase)

         12. Severe anemia (Grade 3; hemoglobin &lt;8.0 g/dL, &lt;4.9 mmol/L, &lt;80 g/L; transfusion
             indicated), Grade 1 white cell counts (lymphocytes &lt;LLN - 800/mm3; &lt;LLN - 0.8 x 109
             /L, neutrophils &lt;LLN - 1500/mm3; &lt;LLN - 1.5 x 109 /L), LLN=Lower Limit Normal Range

         13. Positive serology for human immunodeficiency virus, hepatitis B virus, or hepatitis C
             virus

         14. Significant neuropsychiatric conditions; dementia, major depression, or altered mental
             state that in the opinion of the Investigator will interfere with study participation

         15. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical
             treatments)

         16. Current anticoagulant or anti-platelet treatment (e.g., warfarin, heparins, factor X
             inhibitors, clopidogrel, prasugrel, ticagrelor, or dipyridamole). Low-dose (≤ 325
             mg/day) aspirin is permitted

         17. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1
             year before the screening visit

         18. Use of any investigational drug or device within 3 months before enrollment or current
             participation in a trial that included intervention with a drug or device; or
             currently participating in an investigational drug or device study

         19. Any condition that, in the opinion of the Investigator, could compromise the safety of
             the participant, the participant's ability to communicate with the study staff, or the
             quality of the data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen D Collins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xalud Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Huston</last_name>
    <phone>9259978216</phone>
    <email>mhuston@xaludthera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond Chavez, PhD</last_name>
    <phone>5103879261</phone>
    <email>rchavez@xaludthera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Meza, CCRC</last_name>
      <phone>619-567-1550</phone>
      <email>cmeza@estudysite.com</email>
    </contact>
    <contact_backup>
      <last_name>Angela Anorve</last_name>
      <phone>(619) 567-1550</phone>
      <email>aanorve@estudysite.com</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Overcash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurovations (Napa Pain Institute)</name>
      <address>
        <city>Napa</city>
        <state>California</state>
        <zip>94558</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Cromwell</last_name>
      <phone>707-252-9669</phone>
      <email>hilaryc@napasurgerycenter.com</email>
    </contact>
    <investigator>
      <last_name>Eric Grisgby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Clinical Research Institute</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Brewer</last_name>
      <phone>336-765-6181</phone>
      <phone_ext>146</phone_ext>
      <email>JBrewer@ccrpain.com</email>
    </contact>
    <investigator>
      <last_name>Leonardo Kapural, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Rauck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Adelaide in collaboration with CMAX Clinical Research Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5005</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Pepper</last_name>
      <phone>+61 8 7088 7900</phone>
      <email>dianne.pepper@cmax.com.au</email>
    </contact>
    <investigator>
      <last_name>Mark Rickman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flavia Cicuttini, MD</last_name>
      <phone>+61 3 9903 0158</phone>
      <email>flavia.cicuttini@monash.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anita Wluka, PhD, FRACP, MBBS</last_name>
      <phone>T: +61 3 9903 0994</phone>
      <email>anita.wluka@monash.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Flavia Cicuttini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Pain</keyword>
  <keyword>Interleukin</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>plasmid DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

